{"id":16227,"date":"2012-04-15T22:39:08","date_gmt":"2012-04-16T02:39:08","guid":{"rendered":"http:\/\/www.iposgoode.ca\/?p=16227"},"modified":"2012-04-15T22:39:08","modified_gmt":"2012-04-16T02:39:08","slug":"disclosure-front-and-centre-as-pfizer-prepares-to-defend-viagra-in-supreme-court-of-canada","status":"publish","type":"post","link":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/15\/disclosure-front-and-centre-as-pfizer-prepares-to-defend-viagra-in-supreme-court-of-canada\/","title":{"rendered":"Disclosure Front and Centre as Pfizer Prepares to Defend Viagra in Supreme Court of Canada"},"content":{"rendered":"

This Wednesday, April 18, Pfizer will defend the patent protecting the little blue pill that has changed the lives of men and women around the world.\u00a0 The pill is of course Viagra and the assailant is Teva, a generic pharmaceutical company.\u00a0 Teva applied for a Notice of Compliance in order to market a generic version of Viagra.\u00a0 In the application Teva alleged the patent covering Viagra (446 patent<\/a>) was invalid for lack of utility, obviousness and insufficient disclosure.\u00a0 The Federal Court found that the 446 patent possessed utility, was not obvious, contained adequate disclosure and thus prohibited the Minister of Health from issuing a Notice of Compliance.\u00a0 The Federal Court of Appeal upheld this decision.\u00a0 Teva was granted leave to appeal to the Supreme Court of Canada (SCC).<\/p>\n

<\/p>\n

At first glance this may appear as another case involving a generic pharmaceutical company attempting to gain a share of the market for a successful brand name drug. After reading the factums<\/a> of both sides and examining the issues more closely it becomes clear that there is much more at stake and the decision could have important implications for the patent system as a whole.<\/p>\n

One of the central arguments being advanced by Teva is that the 446 patent is invalid based on insufficient disclosure.\u00a0 Section 27(3)(a) of the Patent Act<\/em><\/a> states, \u201cThe specification of an invention must \u2026 correctly and fully describe the invention and its operation or use as contemplated by the inventor.\u201d\u00a0 This requirement strikes directly at the heart of the patent bargain theory, namely, that in exchange for a limited term monopoly the patentee must completely disclose the invention to the public so that it may practice the invention once the patent has expired.<\/p>\n

The disclosure of Pfizer\u2019s 446 patent explains that the invention relates to the use of a compound of formula (I) or a salt thereof in the treatment of erectile dysfunction. \u00a0The first claim describes formula (I), which gives rise to 260 quintillion possible compounds. The following four claims are for progressively smaller ranges of compounds while claims 6 and 7 each pertain to a single compound.<\/p>\n

Teva\u2019s disclosure argument relies on the following facts: (1) that neither the disclosure nor the claims state that claim 7 contains sildenafil citrate, the compound marketed and sold as Viagra; (2) that sildenafil citrate is the active compound; and (3) that despite Pfizer\u2019s knowledge, it was not disclosed that the remaining compounds in the patent had not been found to treat erectile dysfunction.\u00a0 Teva contends that because, as of the patent filing date, Pfizer knew that sildenafil citrate was the only effective compound, they were required by law to disclose this in the patent.\u00a0 Instead of doing this, Teva asserts that Pfizer artfully worded the patent so as to hide the true identity of its active compound from the public.<\/p>\n

In essence, Pfizer counters by stating a patent specification includes both the descriptive portion and the claims and since an invention is defined by the claims it has met the statutory requirements of disclosure by claiming sildenafil citrate as a single compound in claim 7 of the 446 patent.<\/p>\n

In addition to seeing how the SCC deals with the disclosure issue it will be interesting to see how, if at all, the SCC handles the policy implications that are at stake.\u00a0 Should the Court rule in favor of Pfizer and hold that the disclosure of the 446 patent is sufficient the decision could signal a green light for clever patent lawyers and agents to skillfully draft patents so as to hide crucial information from the public (and competitors) thereby giving the patentee a slight advantage in what can be extremely competitive marketplaces.\u00a0 As such, there will be much more than a share of the erectile dysfunction marketplace at stake when the SCC decides the fate of the Viagra patent.<\/p>\n

Sean Jackson is a JD Candidate at Osgoode Hall Law School.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

This Wednesday, April 18, Pfizer will defend the patent protecting the little blue pill that has changed the lives of men and women around the world.\u00a0 The pill is of course Viagra and the assailant is Teva, a generic pharmaceutical company.\u00a0 Teva applied for a Notice of Compliance in order to market a generic version […]<\/p>\n","protected":false},"author":2140,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","footnotes":""},"categories":[1027,10,184],"tags":[1032],"class_list":["post-16227","post","type-post","status-publish","format-standard","hentry","category-patent-practice","category-patents","category-pharmaceutical-drugs","tag-sean-jackson"],"yoast_head":"\nDisclosure Front and Centre as Pfizer Prepares to Defend Viagra in Supreme Court of Canada - IPOsgoode<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/15\/disclosure-front-and-centre-as-pfizer-prepares-to-defend-viagra-in-supreme-court-of-canada\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Disclosure Front and Centre as Pfizer Prepares to Defend Viagra in Supreme Court of Canada - IPOsgoode\" \/>\n<meta property=\"og:description\" content=\"This Wednesday, April 18, Pfizer will defend the patent protecting the little blue pill that has changed the lives of men and women around the world.\u00a0 The pill is of course Viagra and the assailant is Teva, a generic pharmaceutical company.\u00a0 Teva applied for a Notice of Compliance in order to market a generic version […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/15\/disclosure-front-and-centre-as-pfizer-prepares-to-defend-viagra-in-supreme-court-of-canada\/\" \/>\n<meta property=\"og:site_name\" content=\"IPOsgoode\" \/>\n<meta property=\"article:published_time\" content=\"2012-04-16T02:39:08+00:00\" \/>\n<meta name=\"author\" content=\"ccraig\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ccraig\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/2012\\\/04\\\/15\\\/disclosure-front-and-centre-as-pfizer-prepares-to-defend-viagra-in-supreme-court-of-canada\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/2012\\\/04\\\/15\\\/disclosure-front-and-centre-as-pfizer-prepares-to-defend-viagra-in-supreme-court-of-canada\\\/\"},\"author\":{\"name\":\"ccraig\",\"@id\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/#\\\/schema\\\/person\\\/09b0ef7189d5a2bd6fef2472e5ea5b94\"},\"headline\":\"Disclosure Front and Centre as Pfizer Prepares to Defend Viagra in Supreme Court of Canada\",\"datePublished\":\"2012-04-16T02:39:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/2012\\\/04\\\/15\\\/disclosure-front-and-centre-as-pfizer-prepares-to-defend-viagra-in-supreme-court-of-canada\\\/\"},\"wordCount\":654,\"keywords\":[\"sean jackson\"],\"articleSection\":[\"Patent Practice\",\"Patents\",\"Pharmaceutical Drugs\"],\"inLanguage\":\"en-CA\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/2012\\\/04\\\/15\\\/disclosure-front-and-centre-as-pfizer-prepares-to-defend-viagra-in-supreme-court-of-canada\\\/\",\"url\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/2012\\\/04\\\/15\\\/disclosure-front-and-centre-as-pfizer-prepares-to-defend-viagra-in-supreme-court-of-canada\\\/\",\"name\":\"Disclosure Front and Centre as Pfizer Prepares to Defend Viagra in Supreme Court of Canada - IPOsgoode\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/#website\"},\"datePublished\":\"2012-04-16T02:39:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/#\\\/schema\\\/person\\\/09b0ef7189d5a2bd6fef2472e5ea5b94\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/2012\\\/04\\\/15\\\/disclosure-front-and-centre-as-pfizer-prepares-to-defend-viagra-in-supreme-court-of-canada\\\/#breadcrumb\"},\"inLanguage\":\"en-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/2012\\\/04\\\/15\\\/disclosure-front-and-centre-as-pfizer-prepares-to-defend-viagra-in-supreme-court-of-canada\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/2012\\\/04\\\/15\\\/disclosure-front-and-centre-as-pfizer-prepares-to-defend-viagra-in-supreme-court-of-canada\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Disclosure Front and Centre as Pfizer Prepares to Defend Viagra in Supreme Court of Canada\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/#website\",\"url\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/\",\"name\":\"IPOsgoode\",\"description\":\"An Authoritive Leader in IP\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-CA\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/#\\\/schema\\\/person\\\/09b0ef7189d5a2bd6fef2472e5ea5b94\",\"name\":\"ccraig\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-CA\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4d6461ef50f637a66f0e694df440ca5896971e12de84d604936521b184fec22a?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4d6461ef50f637a66f0e694df440ca5896971e12de84d604936521b184fec22a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4d6461ef50f637a66f0e694df440ca5896971e12de84d604936521b184fec22a?s=96&d=mm&r=g\",\"caption\":\"ccraig\"},\"url\":\"https:\\\/\\\/www.yorku.ca\\\/osgoode\\\/iposgoode\\\/author\\\/ccraig\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Disclosure Front and Centre as Pfizer Prepares to Defend Viagra in Supreme Court of Canada - IPOsgoode","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/15\/disclosure-front-and-centre-as-pfizer-prepares-to-defend-viagra-in-supreme-court-of-canada\/","og_locale":"en_US","og_type":"article","og_title":"Disclosure Front and Centre as Pfizer Prepares to Defend Viagra in Supreme Court of Canada - IPOsgoode","og_description":"This Wednesday, April 18, Pfizer will defend the patent protecting the little blue pill that has changed the lives of men and women around the world.\u00a0 The pill is of course Viagra and the assailant is Teva, a generic pharmaceutical company.\u00a0 Teva applied for a Notice of Compliance in order to market a generic version […]","og_url":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/15\/disclosure-front-and-centre-as-pfizer-prepares-to-defend-viagra-in-supreme-court-of-canada\/","og_site_name":"IPOsgoode","article_published_time":"2012-04-16T02:39:08+00:00","author":"ccraig","twitter_card":"summary_large_image","twitter_misc":{"Written by":"ccraig","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/15\/disclosure-front-and-centre-as-pfizer-prepares-to-defend-viagra-in-supreme-court-of-canada\/#article","isPartOf":{"@id":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/15\/disclosure-front-and-centre-as-pfizer-prepares-to-defend-viagra-in-supreme-court-of-canada\/"},"author":{"name":"ccraig","@id":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/#\/schema\/person\/09b0ef7189d5a2bd6fef2472e5ea5b94"},"headline":"Disclosure Front and Centre as Pfizer Prepares to Defend Viagra in Supreme Court of Canada","datePublished":"2012-04-16T02:39:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/15\/disclosure-front-and-centre-as-pfizer-prepares-to-defend-viagra-in-supreme-court-of-canada\/"},"wordCount":654,"keywords":["sean jackson"],"articleSection":["Patent Practice","Patents","Pharmaceutical Drugs"],"inLanguage":"en-CA"},{"@type":"WebPage","@id":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/15\/disclosure-front-and-centre-as-pfizer-prepares-to-defend-viagra-in-supreme-court-of-canada\/","url":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/15\/disclosure-front-and-centre-as-pfizer-prepares-to-defend-viagra-in-supreme-court-of-canada\/","name":"Disclosure Front and Centre as Pfizer Prepares to Defend Viagra in Supreme Court of Canada - IPOsgoode","isPartOf":{"@id":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/#website"},"datePublished":"2012-04-16T02:39:08+00:00","author":{"@id":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/#\/schema\/person\/09b0ef7189d5a2bd6fef2472e5ea5b94"},"breadcrumb":{"@id":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/15\/disclosure-front-and-centre-as-pfizer-prepares-to-defend-viagra-in-supreme-court-of-canada\/#breadcrumb"},"inLanguage":"en-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/15\/disclosure-front-and-centre-as-pfizer-prepares-to-defend-viagra-in-supreme-court-of-canada\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/2012\/04\/15\/disclosure-front-and-centre-as-pfizer-prepares-to-defend-viagra-in-supreme-court-of-canada\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/"},{"@type":"ListItem","position":2,"name":"Disclosure Front and Centre as Pfizer Prepares to Defend Viagra in Supreme Court of Canada"}]},{"@type":"WebSite","@id":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/#website","url":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/","name":"IPOsgoode","description":"An Authoritive Leader in IP","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-CA"},{"@type":"Person","@id":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/#\/schema\/person\/09b0ef7189d5a2bd6fef2472e5ea5b94","name":"ccraig","image":{"@type":"ImageObject","inLanguage":"en-CA","@id":"https:\/\/secure.gravatar.com\/avatar\/4d6461ef50f637a66f0e694df440ca5896971e12de84d604936521b184fec22a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4d6461ef50f637a66f0e694df440ca5896971e12de84d604936521b184fec22a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4d6461ef50f637a66f0e694df440ca5896971e12de84d604936521b184fec22a?s=96&d=mm&r=g","caption":"ccraig"},"url":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/author\/ccraig\/"}]}},"taxonomy_info":{"category":[{"value":1027,"label":"Patent Practice"},{"value":10,"label":"Patents"},{"value":184,"label":"Pharmaceutical Drugs"}],"post_tag":[{"value":1032,"label":"sean jackson"}]},"featured_image_src_large":false,"author_info":{"display_name":"ccraig","author_link":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/author\/ccraig\/"},"comment_info":"","category_info":[{"term_id":1027,"name":"Patent Practice","slug":"patent-practice","term_group":0,"term_taxonomy_id":1027,"taxonomy":"category","description":"","parent":0,"count":37,"filter":"raw","cat_ID":1027,"category_count":37,"category_description":"","cat_name":"Patent Practice","category_nicename":"patent-practice","category_parent":0},{"term_id":10,"name":"Patents","slug":"patents","term_group":0,"term_taxonomy_id":10,"taxonomy":"category","description":"","parent":0,"count":557,"filter":"raw","cat_ID":10,"category_count":557,"category_description":"","cat_name":"Patents","category_nicename":"patents","category_parent":0},{"term_id":184,"name":"Pharmaceutical Drugs","slug":"pharmaceutical-drugs","term_group":0,"term_taxonomy_id":184,"taxonomy":"category","description":"","parent":0,"count":112,"filter":"raw","cat_ID":184,"category_count":112,"category_description":"","cat_name":"Pharmaceutical Drugs","category_nicename":"pharmaceutical-drugs","category_parent":0}],"tag_info":[{"term_id":1032,"name":"sean jackson","slug":"sean-jackson","term_group":0,"term_taxonomy_id":1032,"taxonomy":"post_tag","description":"","parent":0,"count":8,"filter":"raw"}],"_links":{"self":[{"href":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/wp-json\/wp\/v2\/posts\/16227","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/wp-json\/wp\/v2\/users\/2140"}],"replies":[{"embeddable":true,"href":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/wp-json\/wp\/v2\/comments?post=16227"}],"version-history":[{"count":0,"href":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/wp-json\/wp\/v2\/posts\/16227\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/wp-json\/wp\/v2\/media?parent=16227"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/wp-json\/wp\/v2\/categories?post=16227"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.yorku.ca\/osgoode\/iposgoode\/wp-json\/wp\/v2\/tags?post=16227"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}